Gilead Sciences, Inc.
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
1839 articles with Gilead Sciences, Inc.
-
Two of the biggest drugmakers in the HIV space are teaming up on a combination therapy that has the potential to be a game-changer for patients diagnosed with the dangerous virus for which there is no known cure.
-
Genentech Provides Update on the Phase III REMDACTA Trial of Actemra Plus Veklury in Patients With Severe COVID-19 Pneumonia
3/11/2021
The REMDACTA clinical trial of Actemra plus Veklury did not meet its primary endpoint of improved time to hospital discharge for patients with severe COVID-19 pneumonia or its key secondary endpoints compared to Veklury alone
-
Gilead’s Investigational Lenacapavir Demonstrates Sustained Long-Acting Efficacy Through Week 26 in Data Presented at CROI
3/9/2021
Gilead Sciences, Inc. (Nasdaq: GILD) today presented additional results from the Phase 2/3 CAPELLA trial evaluating the company’s investigational, long-acting HIV-1 capsid inhibitor, lenacapavir, in heavily treatment-experienced people with multi-drug resistant HIV-1 infection
-
The U.S. FDA approved Gilead and Kite’s Yescarta (axicabtagene ciloleucel) for adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
-
Gilead Sciences Completes Acquisition of MYR GmbH
3/4/2021
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire MYR GmbH for up to approximately €1.45 billion in aggregate cash consideration. The acquisition provides Gilead with Hepcludex ® (bulevirtide), which was conditionally approved by the European Medicines Agency for the treatment of chronic hepatitis delta virus (HDV) in adults
-
The biopharma industry remained strong, as demand for COVID-related products skyrocketed. However, some companies are facing layoffs. Here's a brief overview.
-
Gilead to Present New Data at CROI 2021 Demonstrating the Company's Commitment to Addressing Urgent Global Health Needs
3/2/2021
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new data from the company’s HIV, hepatitis C virus (HCV), and COVID-19 research and development programs at the 28th Conference on Retroviruses and Opportunistic Infections (virtual CROI 2021) taking place from March 6-10
-
Orna, which began as an academic query at the Massachusetts Institute of Technology (MIT), is a biotechnology company creating fully engineered circular RNA, or O-shaped RNA therapies for the treatment of cancer, autoimmune, and genetic disorders.
-
Gilead Sciences to Present at Upcoming Investor Conferences
2/18/2021
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 1:40 p.m. EST Cowen Annual Health Care Conference on Thursday, March 4, 2021 at 12:10 p.m. EST
-
Galapagos and Gilead Discontinue ISABELA Phase 3 Trials in IPF
2/10/2021
Galapagos NV (Euronext & Nasdaq: GLPG) and Gilead Sciences (Nasdaq: GILD) today announced the decision to halt the ISABELA Phase 3 clinical studies with the investigational autotaxin inhibitor ziritaxestat in patients with idiopathic pulmonary fibrosis.
-
Belgium-based Galapagos NV and Foster City, California-based Gilead Sciences halted the ISABELA Phase III clinical trial of ziritaxestat in idiopathic pulmonary fibrosis.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 9, 2021.
-
Kite Appoints Frank Neumann as Worldwide Head of Clinical Development
2/8/2021
Industry Leader in Cell Therapy and Oncology Drug Development Positioned for Continued Advancement of Kite’s Clinical Programs
-
Gilead’s Inhaled COVID-19 Treatment, Remdesivir, Requires More Adequate Testing Before Regulatory...
2/5/2021
Foster City-based Gilead Sciences says its inhaled version of remdesivir, which has been increasingly used in research and practice to combat COVID-19 in hospitalized patients, won’t be available any time soon as it needs more testing in clinical research. -
Gilead Sciences Announces Fourth Quarter and Full Year 2020 Financial Results
2/4/2021
Fourth Quarter 2020 Year-Over-Year: - Product Sales increased 26% to $7.3 billion, primarily due to Veklury ® (remdesivir) - - Diluted EPS of $1.23; Non-GAAP Diluted EPS of $2.19 - Full Year 2020 Year-Over-Year: - Product Sales increased 10% to $24.4 billion, primarily due to Veklury - - Diluted EPS of $0.10; Non-GAAP Diluted EPS of $7.09 -
-
Gilead Sciences Announces 4.4 Percent Increase in First Quarter 2021 Dividend
2/4/2021
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 4.4% in the company’s quarterly cash dividend, beginning in the first quarter of 2021.
-
Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone’s Vaccine Platform Technology for HIV Cure
2/1/2021
Gilead Sciences, Inc. and Gritstone Oncology, Inc. announced that the companies have entered into a collaboration, option and license agreement to research and develop a vaccine-based immunotherapy as part of Gilead’s efforts to find a curative treatment for human immunodeficiency virus infection.
-
Gilead Sciences has inked a collaboration, option and license deal with Gritstone Oncology to create a vaccine-based immunotherapy as a cure for HIV.
-
Gilead Sciences to Release Fourth Quarter and Full Year 2020 Financial Results on Thursday, February 4, 2021
1/21/2021
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2020 financial results will be released on Thursday, February 4, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s fourth quarter and full year 2020 financial results and will provide a business update.
-
Clinical Catch-Up: January 11-15
1/18/2021
The year is starting to pick up in terms of clinical trial announcements. Here’s a look at last week’s news.